Posted by Michael Wonder on 07 May 2025
Adcentrx Therapeutics granted fast track designation for ADRX-0706 nectin-4 antibody drug conjugate for the treatment of advanced cervical cancer
6 May 2025 - Adcentrx Therapeutics today announced that the US FDA has granted fast track designation to its lead program, ADRX-0706, for the treatment of patients with locally advanced or metastatic squamous cell cervical cancer.
ADRX-0706 is a nectin-4 antibody drug conjugate being evaluated in the Phase 1b portion of an on-going Phase 1a/b clinical trial for the treatment of select advanced solid tumours, including cervical cancer.
